PDCD1 and neoplasm: The current study identifies a new bispecific modality that simultaneously inhibits PD‐1/PD‐L1 and RANK/RANKL in the TME, providing benefit in ICI‐resistant settings and demonstrating superior anti‐tumor control compared with the combination of parental anti‐RANKL plus anti‐PD‐1 antibodies.